SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gets final approval from USFDA for Doxycycline Hyclate Capsules

02 Jun 2018 Evaluate

Zydus Cadila has received final approval from US Food and Drug Administration (USFDA), to market Doxycycline Hyclate Capsules USP, 50 mg and 100mg. It is a tetracycline antibiotic used for treatment of a wide variety of bacterial infections, including those that cause acne. This medication is also used for prophylaxis of malaria.

It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad. The group has now more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

931.50 2.65 (0.29%)
22-Apr-2026 12:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.60
Dr. Reddys Lab 1220.35
Cipla 1233.90
Zydus Lifesciences 931.50
Lupin 2308.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×